Glenmark Pharmaceuticals antibody ‘GBR 830’ completes clinical phase 1 studies
Advertisement
Glenmark Pharmaceuticals is reported to have completed the clinical phase I studies for its novel monoclonal antibody 'GBR 830' for treating autoimmune diseases in Netherlands.
As further reported by PTI, the phase 11 studies for the antibody will be conducted in the US and Europe. Preparations for initiating Phase II studies in both atopic dermatitis and celiac disease in the US and Europe are well advanced, the company expects studies to commence in the next few months, it added in a statement.
"Glenmark Pharmaceuticals S.A., a wholly owned Swiss subsidiary of Glenmark Pharmaceuticals Ltd announced today that GBR 830, a novel monoclonal antibody has completed clinical phase 1 dosing," Glenmark Pharmaceuticals said.
Glenmark Pharma Chairman & MD Glenn Saldanha said: "We are excited about the progress of GBR 830, the first OX40 antagonist globally to successfully complete Phase 1 studies."
OX40 is a very well validated target with the potential to treat a wide array of autoimmune diseases, he added.
As further reported by PTI, the phase 11 studies for the antibody will be conducted in the US and Europe. Preparations for initiating Phase II studies in both atopic dermatitis and celiac disease in the US and Europe are well advanced, the company expects studies to commence in the next few months, it added in a statement.
"Glenmark Pharmaceuticals S.A., a wholly owned Swiss subsidiary of Glenmark Pharmaceuticals Ltd announced today that GBR 830, a novel monoclonal antibody has completed clinical phase 1 dosing," Glenmark Pharmaceuticals said.
Glenmark Pharma Chairman & MD Glenn Saldanha said: "We are excited about the progress of GBR 830, the first OX40 antagonist globally to successfully complete Phase 1 studies."
OX40 is a very well validated target with the potential to treat a wide array of autoimmune diseases, he added.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.